X0202 SCHEDULE 13G/A 0001231919-25-000627 0001863769 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 03/31/2026 0001420720 iBio, Inc. 451033708 11750 Sorrento Valley Road, Suite 200 San Diego CA 92121 Rule 13d-1(c) Frazier Life Sciences Public Fund, L.P. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 5.7 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based on 34,543,561 shares of Common Stock outstanding on February 9, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on February 10, 2026. FHMLSP, L.P. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 5.7 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based on 34,543,561 shares of Common Stock outstanding on February 9, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on February 10, 2026. FHMLSP, L.L.C. b DE 0.00 1953467.00 0.00 1953467.00 1953467.00 5.7 OO The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. The percentage listed in row 11 is calculated based on 34,543,561 shares of Common Stock outstanding on February 9, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on February 10, 2026. Frazier Life Sciences XI, L.P. b DE 0.00 0.00 0.00 0.00 0.00 0.0 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. FHMLS XI, L.P. b DE 0.00 0.00 0.00 0.00 0.00 0.0 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. FHMLS XI, L.L.C. b DE 0.00 0.00 0.00 0.00 0.00 0.0 OO The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. Frazier Life Sciences XII, L.P. b DE 0.00 0.00 0.00 0.00 0.00 0.0 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. FHMLS XII, L.P. b DE 0.00 0.00 0.00 0.00 0.00 0.0 PN The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. FHMLS XII, L.L.C. b DE 0.00 0.00 0.00 0.00 0.00 0.0 OO The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Statement. iBio, Inc. 11750 Sorrento Valley Road, Suite 200, San Diego, CA, 92121. The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304 The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G/A is incorporated by reference. Y The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 1,953,467 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 0 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 0 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Pre-Funded Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Pre-Funded Warrants to purchase 7,557,258 shares of Common Stock, (ii) FLS XI holds Pre-Funded Warrants to purchase 70,668 shares of Common Stock, and (iii) FLS XII holds Pre-Funded Warrants to purchase 886,335 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Pre-Funded Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G/A (including the footnotes thereto) is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Frazier Life Sciences Public Fund, L.P. /s/ Jennifer Martin 05/12/2026 FHMLSP, L.P. /s/ Jennifer Martin 05/12/2026 FHMLSP, L.L.C. /s/ Jennifer Martin 05/12/2026 Frazier Life Sciences XI, L.P. /s/ Jennifer Martin 05/12/2026 FHMLS XI, L.P. /s/ Jennifer Martin 05/12/2026 FHMLS XI, L.L.C. /s/ Jennifer Martin 05/12/2026 Frazier Life Sciences XII, L.P. /s/ Jennifer Martin 05/12/2026 FHMLS XII, L.P. /s/ Jennifer Martin 05/12/2026 FHMLS XII, L.L.C. /s/ Jennifer Martin 05/12/2026